Nestlé to enter fast-growing global market for clinical nutrition products for people with inherited metabolic disorders
(Thomson Reuters ONE) -
Nestlé S.A. /
Nestlé to enter fast-growing global market for clinical nutrition products for
people with inherited metabolic disorders
Processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this announcement.
Vevey, 2 August 2010 - Nestlé today announced that it has completed the
acquisition of Vitaflo, a Liverpool-based global provider of clinical
nutritional products which has enjoyed double-digit growth in the order of 30%
over the last 3 years. This strategic transaction allows Nestlé to enter the
fast-growing global market for clinical nutrition products tailor-made for
people with inherited metabolic disorders. This sector is growing rapidly as
improved diagnosis and screening enable increasing numbers of cases to be
detected, and new advances in science demonstrate the benefits of specialised
nutrition as an integral part of clinical management. Vitaflo has approximate
annual sales of CHF 40 million. The acquisition price is not disclosed.
Vitaflo's products are developed for infants, children and adults with genetic
disorders that affect how food is processed by the body. These include
phenylketonuria (PKU), maple syrup urine disease (MSUD) and homocystinuria
(HCU). Inborn errors of metabolism are infrequent at an estimated 1 in
2,500-50,000 births depending on the disorder but persist from birth to
adulthood. They constitute a significant proportion of genetic disorders
detected in newborn babies.
Vitaflo's successful business model is underpinned by its leading science,
research and product development. It is well aligned with Nestlé's global
commitment to develop innovative nutritional solutions with proven health
benefits, and to work with health care providers and caregivers in offering
foods for people with specific nutritional needs.
"This acquisition is an excellent strategic fit, reinforcing our position in a
rapidly growing segment of specialised nutrition. Vitaflo's science-based
products complement and support our business in the area of high-technology
personalised nutrition. Additionally, Vitaflo will benefit from Nestlé's
commitment to innovation in nutrition, health and wellness. Our strong
geographic presence will enable Vitaflo to enter into a global market," said
Paul Bulcke, CEO of Nestlé.
Richard Laube, CEO of Nestlé Nutrition, said, "We are delighted to welcome
Vitaflo into our company, whose people bring with them valuable expertise and
know-how in clinical nutrition. This will help us to expand our innovation
potential in the area of high quality products for infants, children and adults
with very specific nutritional needs."
For more information about Vitaflo, please visit www.vitaflo.co.uk
Contacts
Media: Robin Tickle Tel.: +41 (0)21 924 22 00
Investors: Roddy Child-Villiers Tel.: +41 (0)21 924 36 22
[HUG#1435201]
--- End of Message ---
Nestlé S.A.
Avenue Nestlé 55 Vevey null
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Nestlé S.A. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 02.08.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 38431
Anzahl Zeichen: 0
contact information:
Town:
Vevey
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 220 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nestlé to enter fast-growing global market for clinical nutrition products for people with inherited metabolic disorders"
steht unter der journalistisch-redaktionellen Verantwortung von
Nestlé S.A. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).





